 |
Our product development efforts, including those of our licensing
partners, cover a wide range of medical conditions. The following tables
summarize potential therapeutic indications and development stages for
our Strategic Assets (the antibody products in which Medarex has direct
commercial opportunity) and our Financial Assets (late-stage programs of
our licensing partners, based on publicly available information).
Strategic Assets in Clinical Development
| Product Candidate | Indication | Clinical Status | Partner/Licensee |
|---|
Ipilimumab
anti-CTLA4 |
Melanoma, Prostate Cancer, Lung Cancer and Others |
Phase 3 and earlier |
Bristol-Myers Squibb
Co-promote/Profit share |
MDX-1100
anti-IP10 |
Ulcerative Colitis, Rheumatoid Arthritis |
Phase 2 |
Wholly-owned
|
MEDI-545 and MEDI-546
anti-IFNα Pathway |
Lupus and Autoimmune Diseases |
Phase 2 and earlier |
MedImmune/AstraZeneca
Co-promote option |
MDX-1342
anti-CD19 |
Chronic Lymphocytic Leukemia, Rheumatoid Arthritis |
Phase 1 |
Wholly-owned
|
MDX-1106 (ONO-4538)
anti-PD1 |
Cancer, Hepatitis C |
Phase 1 |
Ono Pharmaceutical
Co-development |
MDX-1105
anti-PD-L1 |
Cancer |
Phase 1 |
Wholly-owned
|
MDX-1401
anti-CD30 |
Hodgkin Lymphoma |
Phase 1 |
Wholly-owned
|
MDX-1411
anti-CD70 |
Cancer |
Phase 1 |
Wholly-owned
|
MDX-1203
anti-CD70 Antibody-Drug Conjugate |
Cancer |
Phase 1 |
Wholly-owned
|
ValortimTM (MDX-1303)
anti-B. anthracis PA |
Anthrax Infection |
Phase 1 |
PharmAthene
Co-development |
Selected Financial Assets in Late-Stage Clinical Development
| Product Candidate | Indication | Clinical Status | Partner/Licensee |
|---|
STELARATM (ustekinumab)
anti-IL12/IL23 |
Psoriasis |
Approved in Canada and Europe |
Centocor Ortho Biotech
Milestones/Royalties |
SIMPONITM (golimumab)
anti-TNFα |
Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis |
Approved in Canada and U.S. |
Centocor Ortho Biotech
Milestones/Royalties |
Ilaris® (canakinumab)
anti-IL1β |
Cryopirin-associated Periodic Syndromes |
Approved in U.S. |
Novartis Pharma
Milestones/Royalties |
Ofatumumab (HuMax-CD20)
anti-CD20 |
Chronic Lymphocytic Leukemia, Rheumatoid Arthritis |
BLA/MAA Filed |
Genmab/GlaxoSmithKline
Equity Interest |
Zalutumumab (HuMax-EGFR)
anti-EGFR |
Head and Neck Cancer |
Phase 3 |
Genmab
Equity Interest |
MDX-066 (CDA-1) +
MDX-1388 (CDA-2)
anti-C. difficile Toxin A and Toxin B |
C. difficile Infection |
Phase 2 |
Merck & Co.
Co-development* |
* All payments divided equally between Medarex and co-development partner, MBL.
We are aware of other antibody candidates derived from our UltiMAb®
technology that are in Phase 2 or Phase 1 clinical development by
partners who license our technology, including Amgen, Bristol-Myers
Squibb, Centocor Ortho Biotech, Eli Lilly, Genmab/Roche, ImClone Systems, Novartis and
Pfizer. We are not obligated, and in many cases due to contractual
obligations, are unable to provide any clinical data and/or development
progress updates on these antibody programs.
©2001-2009 Medarex, Inc. All rights reserved. - Legal Disclaimer - Trademarks
- Privacy Policy
|
|
